Thelansis’s "Antibody-Mediated Rejection (AMR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Antibody-Mediated Rejection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Antibody-mediated rejection (AMR) is a complex immune response and the leading cause of late allograft loss in kidney transplant recipients, occurring when the host's B-cells and plasma cells produce donor-specific antibodies (DSA) that target the graft's vascular endothelium. Under the Banff classification, the condition is categorized into active, chronic active, and chronic (inactive) AMR, based on the presence of microvascular inflammation, complement deposition (C4d), and structural changes like glomerular basement membrane doubling. Diagnosis and monitoring rely on a multimodal assessment of renal function (serum creatinine and proteinuria), DSA titers, and histopathological findings from graft biopsies. Although there are currently no FDA-approved therapies specifically for AMR, management centers on a "multi-hit" approach tailored to the underlying pathophysiology: this includes removing circulating antibodies via plasmapheresis, neutralizing antibodies with intravenous immunoglobulin (IVIg), and depleting antibody-producing cells using rituximab (anti-CD20) or proteasome inhibitors like bortezomib.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Antibody-Mediated Rejection (AMR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Antibody-Mediated Rejection (AMR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.